Different jobs. Urolithin A has the better randomized evidence for aging muscle — endurance and strength gains in short trials, nearly all manufacturer-funded. Ubiquinol's real signal is cardiac: Q-SYMBIO and a 33-trial meta-analysis in heart failure, which a Cochrane review still rates low certainty. Healthy and training? Urolithin A. Already in cardiology care? CoQ10, with your clinician. Neither is a proven lifespan intervention.
| Compared on | Urolithin A | Ubiquinol / CoQ10 |
|---|---|---|
| Evidence grade | Moderate evidence | Moderate evidence |
| What it is | Urolithin A is a natural compound produced by gut bacteria from ellagitannins and ellagic acid, dietary polyphenols found in pomegranates, walnuts, and berries. | Coenzyme Q10 (CoQ10, ubiquinone) is a fat-soluble compound the body synthesizes and also obtains in small amounts from foods such as oily fish, organ meats, and nuts. |
| Best human evidence | “Urolithin A is a gut microbiome-derived metabolite shown to stimulate mitophagy and improve muscle function” JAMA Netw Open 2022 · PMID 35050355 | “The primary long-term endpoint was reached by 15% of the patients in the CoQ10 group versus 26% in the placebo group (hazard ratio: 0.50; 95% confidence interval: 0.32 to 0.80; p = 0.003)…” JACC Heart Fail 2014 · PMID 25282031 |
| Dose / protocol studied | 1,000 mg/day in most trials (500–1,000 mg/day studied) | 100–400 mg/day (1,500 mg/day used in a multiple-system-atrophy trial) |
| Typical listed price | $50.00 | $49.03 |
| Who it suits | A healthy adult over about 40 who trains and wants the mitophagy mechanism with the most direct human muscle trials behind it. | Someone whose CoQ10 is plausibly depleted — on a statin, in heart-failure care, or with high oxidative demand — working with a clinician. |
| Who should skip it | Anyone who wants long-term outcome data, or who is uncomfortable that almost every trial was funded by the ingredient's manufacturer. | A healthy person buying it for longevity: no trial shows CoQ10 extends lifespan in healthy people, and Cochrane found no clinically significant blood-pressure effect in primary hypertension. |
| Key caveat | Several small, well-controlled randomized trials show improved muscle endurance and strength, lower inflammatory markers, and younger-looking immune-cell profiles, with an excellent safety record. But nearly all are short (4 months or less) and manufacturer-funded, some missed their primary endpoints, and there is no long-term disease or lifespan data. Most people cannot reliably make urolithin A from food — the rationale for direct supplementation. | The strongest signal is adjunctive therapy in chronic heart failure (the Q-SYMBIO trial plus a 33-trial meta-analysis), but a Cochrane review rates that evidence low certainty, and most large trials used ubiquinone rather than ubiquinol — ubiquinol's proven advantage is mainly absorption. Benefit is clearest where CoQ10 is depleted (statins, heart failure, high oxidative demand); it is not a proven lifespan intervention in healthy people. |
Urolithin A lists at about 1.0× the price of Ubiquinol / CoQ10. Prices are the typical listed prices in our catalog, not live Amazon prices, and a true cost-per-studied-dose is not shown because our catalog does not record servings per container — we would have to guess, so we don't.
These are not substitutes. They act at different points in the mitochondrion, and their evidence sits in different populations.
Urolithin A. The JAMA Network Open randomized trial in older adults is the cleanest human result either compound has: better muscle endurance and improved mitochondrial biomarkers. Note that a 2024 systematic review found it raised strength and endurance but had no effect on anthropometrics, cardiovascular outcomes or physical function.
CoQ10, and ask your clinician. Statins inhibit a biosynthetic pathway shared with cholesterol and lower endogenous CoQ10. Benefit is clearest where CoQ10 is depleted — but be aware one meta-analysis found no benefit for statin-associated muscle pain.
CoQ10 — as an addition your cardiologist knows about, never a substitute. Q-SYMBIO reported the primary long-term endpoint reached by 15% on CoQ10 versus 26% on placebo, and a 2024 meta-analysis of 33 heart-failure trials found lower mortality. Cochrane still rates the certainty low, and much of the mortality data comes from CoQ10 combined with selenium.
Probably Urolithin A anyway. Urolithin A is not present in food; gut bacteria make it from ellagitannins, and the capacity to do so varies widely between people. That variability is the actual rationale for supplementing it directly.
If the goal is a longer life rather than a specific measurable effect, neither compound has earned it. Urolithin A has no long-term disease or mortality data at all, and the heart-failure crossover trial on this page found no positive effect on echocardiographic or biochemical indices in reduced-ejection-fraction patients.
Both are also downstream of something free: mitochondrial biogenesis responds to endurance training, which is the intervention every one of these mechanisms is modelled on.
Cited: Rev Recent Clin Trials 2024 · PMID 38415449 · Ageing Res Rev 2024 · PMID 39002645
Each quote below is taken verbatim from the cited paper. Null and negative results are included on purpose — they are the reason a grade means anything.
“Urolithin A is a gut microbiome-derived metabolite shown to stimulate mitophagy and improve muscle function”
“These findings indicate that short-term UA supplementation modulates human immune cell composition and function, supporting its potential to counteract age-related immune decline and inflammaging.”
“The results of the present study do not support any positive effect of UA supplementation in improving echocardiographic and biochemical indices of HFrEF.”
“The primary long-term endpoint was reached by 15% of the patients in the CoQ10 group versus 26% in the placebo group (hazard ratio: 0.50; 95% confidence interval: 0.32 to 0.80; p = 0.003) by intention-to-treat analysis.”
“CoQ10 supplementation significantly reduced systolic blood pressure (SBP) (-4.77 mmHg, 95% CI: -6.57, -2.97) in patients with cardiometabolic diseases”
“During a follow up time of 5.2 years a significant reduction of cardiovascular mortality was found in the active treatment group vs. the placebo group (5.9% vs. 12.6%; P=0.015).”
Links go to an Amazon search for the product name, not to a specific listing, so you can compare sellers, price and third-party testing yourself.
For skeletal muscle in healthy older adults, urolithin A has the more direct randomized evidence. For cardiac endpoints, CoQ10 has the larger and older trial base. They are graded the same — Moderate — for different reasons.
There is no human trial of the combination, so any claim about synergy is theoretical. Both have good safety records at studied doses. Discuss it with your clinician, particularly if you take cardiac medication.
Most trials used 1,000 mg/day, with 500–1,000 mg/day studied. CoQ10 trials mostly used 100–400 mg/day, and a multiple-system-atrophy trial used 1,500 mg/day of ubiquinol.
Several pharmacokinetic studies show better oral absorption for ubiquinol. But most of the large outcome trials used ubiquinone, so ubiquinol's proven advantage is absorption, not outcomes.
Neither is a proven senolytic in people. Quercetin has the better human data — meta-analyses show a 2–3 mmHg…
Creatine, unless you cannot train. It is the only compound in this pair graded Strong: meta-analyses of…
Neither, on current human evidence. Spermidine's most rigorous trial — twelve months at the 0.9 mg/day dose…